Enhanced expression of the transcriptional activators YAP and TAZ in non-secreting pituitary tumours

2018 ◽  
Author(s):  
Paraskevi Xekouki ◽  
Emily Lodge ◽  
Ran Li ◽  
Jorg Flitsch ◽  
Stefan Bornstein ◽  
...  
Keyword(s):  
Transcriptional Activators ◽  
Pituitary Tumours ◽  
Enhanced Expression

scholarly journals Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ

2019 ◽  
Vol 26 (1) ◽  
pp. 215-225 ◽  
Author(s):  
Paraskevi Xekouki ◽  
Emily J Lodge ◽  
Jakob Matschke ◽  
Alice Santambrogio ◽  
John R Apps ◽  
...  
Keyword(s):  
Cell Fate ◽  
Cell Types ◽  
Pituitary Tumours ◽  
Null Cell ◽  
Human Pituitary ◽  
Enhanced Expression ◽  
Kinase Cascade ◽  
Mouse Pituitary

Tumours of the anterior pituitary can manifest from all endocrine cell types but the mechanisms for determining their specification are not known. The Hippo kinase cascade is a crucial signalling pathway regulating growth and cell fate in numerous organs. There is mounting evidence implicating this in tumour formation, where it is emerging as an anti-cancer target. We previously demonstrated activity of the Hippo kinase cascade in the mouse pituitary and nuclear association of its effectors YAP/TAZ with SOX2-expressing pituitary stem cells. Here, we sought to investigate whether these components are expressed in the human pituitary and if they are deregulated in human pituitary tumours. Analysis of pathway components by immunofluorescence reveals pathway activity during normal human pituitary development and in the adult gland. Poorly differentiated pituitary tumours (null-cell adenomas, adamantinomatous craniopharyngiomas (ACPs) and papillary craniopharyngiomas (PCPs)), displayed enhanced expression of pathway effectors YAP/TAZ. In contrast, differentiated adenomas displayed lower or absent levels. Knockdown of the kinase-encoding Lats1 in GH3 rat mammosomatotropinoma cells suppressed Prl and Gh promoter activity following an increase in YAP/TAZ levels. In conclusion, we have demonstrated activity of the Hippo kinase cascade in the human pituitary and association of high YAP/TAZ with repression of the differentiated state both in vitro and in vivo. Characterisation of this pathway in pituitary tumours is of potential prognostic value, opening up putative avenues for treatments.

scholarly journals Three-Component Repurposed Technology for Enhanced Expression: Highly Accumulable Transcriptional Activators via Branched Tag Arrays

2018 ◽  
Vol 1 (5) ◽  
pp. 337-347 ◽  
Author(s):  
Atsushi Kunii ◽  
Yoshihiro Hara ◽  
Mitsumasa Takenaga ◽  
Naoko Hattori ◽  
Takuya Fukazawa ◽  
...  
Keyword(s):  
Transcriptional Activators ◽  
Enhanced Expression

Enhanced expression of TGFβ, collagen, and TIMP-1 genes in esophageal stricture

2001 ◽  
Vol 120 (5) ◽  
pp. A153-A153
Author(s):  
M KLINE ◽  
Z ZANG ◽  
K PATEL ◽  
S FRENCH ◽  
H TSUKAMOTO
Keyword(s):  
Esophageal Stricture ◽  
Enhanced Expression

Anti-Diabetic Activity of a Mineraloid Isolate, in vitro and in Genetically Diabetic Mice

2011 ◽  
Vol 81 (1) ◽  
pp. 34-42 ◽  
Author(s):  
Joel Deneau ◽  
Taufeeq Ahmed ◽  
Roger Blotsky ◽  
Krzysztof Bojanowski
Keyword(s):  
Dna Microarrays ◽  
Human Fibroblasts ◽  
Diabetic Animal ◽  
In Vitro Tests ◽  
Diabetic Mice ◽  
Fossil Material ◽  
Expression Of Genes ◽  
Enhanced Expression ◽  
Genetically Diabetic Mice

Type II diabetes is a metabolic disease mediated through multiple molecular pathways. Here, we report anti-diabetic effect of a standardized isolate from a fossil material - a mineraloid leonardite - in in vitro tests and in genetically diabetic mice. The mineraloid isolate stimulated mitochondrial metabolism in human fibroblasts and this stimulation correlated with enhanced expression of genes coding for mitochondrial proteins such as ATP synthases and ribosomal protein precursors, as measured by DNA microarrays. In the diabetic animal model, consumption of the Totala isolate resulted in decreased weight gain, blood glucose, and glycated hemoglobin. To our best knowledge, this is the first description ever of a fossil material having anti-diabetic activity in pre-clinical models.

TRANSFORMATION OF PITUITARY TUMOURS FROM PROLACTIN-INTO TSH-CELL TYPE II. ENDOCRINE ASPECTS

1965 ◽  
Vol 49 (3_Suppl) ◽  
pp. S162 ◽  
Author(s):  
H. G. Kwa ◽  
Constance A. Feltkamp
Keyword(s):  
Type Ii ◽  
Cell Type ◽  
Pituitary Tumours
Sign in / Sign up

Export Citation Format

Share Document